Ecosyste.ms: Papers
An open API service providing mapping between scientific papers and software projects that are mentioned in them.
All mentions data is based on the CZI Software Mentions dataset.
Projects: cran: CONCUR
https://packages.ecosyste.ms/registries/cran.r-project.org/packages/CONCUR
Copy Number Profile Curve-Based Association Test
3 versions
Latest release: over 2 years ago
205 downloads last month
Papers Mentioning CONCUR 23
10.1007/s00432-020-03290-y
Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trialsCited by: 10
Author(s): Arndt Stahler, Volker Heinemann, Ingrid Ricard, Jobst C. von Einem, Clemens Gießen-Jung, C. Benedikt Westphalen, Marlies Michl, Kathrin Heinrich, Lisa Miller-Phillips, Ivan Jelas, Sebastian Stintzing, Dominik Paul Modest
Software Mentions: 3
Published: over 4 years ago
10.1371/journal.pcbi.1007797
Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysisCited by: 6
Author(s): Amanda Brucker, Wenbin Lu, Rachel West, Qi You Yu, Chuhsing Kate Hsiao, Tzu Hung Hsiao, Ching Heng Lin, Patrik K. E. Magnusson, Patrick F. Sullivan, Jin P. Szatkiewicz, Tzu-Pin Lu, Jung Ying Tzeng
Software Mentions: 2
Published: over 4 years ago
10.1371/journal.pone.0239439
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancerCited by: 4
Author(s): Yuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, Shu Cao, Wu Zhang, Satoshi Okazaki, Martin D. Berger, Satoshi Matsusaka, Dongyun Yang, Yan Ning, Hideo Baba, Fotios Loupakis, Sara Lonardi, Filippo Pietrantonio, Beatrice Borelli, Chiara Cremolini, Toshiharu Yamaguchi
Software Mentions: 2
Published: about 4 years ago
10.1093/bioinformatics/btaa733
CONCUR: quick and robust calculation of codon usage from ribosome profiling dataCited by: 4
Author(s): Michaela Frye, Susanne Bornelöv
Software Mentions: 2
Published: about 4 years ago
10.18632/oncotarget.20054
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancerCited by: 28
Author(s): Valentina Belli, Vincenzo Sforza, Claudia Cardone, Erika Martinelli, Giusi Barra, Nunzia Matrone, Stefania Napolitano, Floriana Morgillo, Concetta Tuccillo, Alessandro Di Federico, Marcello Dallio, Carmelina Loguercio, Antonietta Gerarda Gravina, Raffaele De Palma, Fortunato Ciardiello, Teresa Troiani
Software Mentions: 2
Published: over 7 years ago
10.1002/1878-0261.12972
Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentCited by: 10
Author(s): Brice Pastor, André Thewis, Julie Henriques, Isabelle Trouilloud, Christophe Tournigand, Marine Jary, Thibault Mazard, Christophe Louvet, Simon Azan, Audrey Bauer, Benoît Roch, Colline Sanchez, Déwi Vernerey, Alain R. Thierry, Antoine Adenis
Software Mentions: 2
Published: over 3 years ago
10.3389/fcell.2021.660924
Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment GuidanceCited by: 23
Author(s): Omayma Mazouji, Abdelhak Ouhajjou, Roberto Incitti, Hicham Mansour
Software Mentions: 1
Published: over 3 years ago
10.3389/fonc.2020.587692
Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard TherapiesCited by: 3
Author(s): Lei Wang, Huijiao Cao, Chang Jiang, Weiling He, Yafei You, Kangqiang Peng, Yong Jin, Liangping Xia
Software Mentions: 1
Published: almost 4 years ago
10.1017/gmh.2015.5
Designing and evaluating Brain Powered Games for cognitive training and rehabilitation in at-risk African childrenCited by: 20
Author(s): Bruno Giordani, Bryan Novak, Alla Sikorskii, Paul Bangirana, Noeline Nakasujja, Brian Winn, Michael J. Boivin
Software Mentions: 1
Published: almost 10 years ago
10.3390/jcm9061772
Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer PatientsCited by: 3
Author(s): Matthias Unseld, Sebastian Fischöder, Mathias Jachs, Magdalena Drimmel, Alexander Siebenhüner, Daniela Bianconi, Markus Kieler, Hannah Christina Puhr, Christoph Minichsdorfer, Thomas Winder, Gerald W. Prager
Software Mentions: 1
Published: over 4 years ago
10.1038/s41598-018-22302-z
Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective studyCited by: 28
Author(s): Miaomiao Gou, Haiyan Si, Yong Zhang, Niansong Qian, Zhikuan Wang, Weiwei Shi, Guanghai Dai
Software Mentions: 1
Published: over 6 years ago
10.1186/s13063-019-3917-z
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trialCited by: 4
Author(s): Cheng‐Jen Ma, Tsung‐Kun Chang, Hsiang‐Lin Tsai, Wei‐Chih Su, Ching‐Wen Huang, Yung‐Sung Yeh, Yu‐Tang Chang, Jaw‐Yuan Wang
Software Mentions: 1
Published: almost 5 years ago
10.1186/s13045-016-0384-9
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II studyCited by: 45
Author(s): Rui Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, ST Fan, Yi-Jun Hua, Weiguo Su
Software Mentions: 1
Published: almost 8 years ago
10.1186/s13045-019-0718-5
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapyCited by: 186
Author(s): Shuang Qin, An‐Ping Li, Ming Yi, Shengnan Yu, Mingsheng Zhang, Kongming Wu
Software Mentions: 1
Published: over 5 years ago
10.3390/ijms18071522
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentCited by: 24
Author(s): Alessia Bignucolo, Elena De Mattia, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli
Software Mentions: 1
Published: over 7 years ago
10.18632/oncotarget.9187
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancerCited by: 39
Author(s): Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Takeru Wakatsuki, Yuki Horiike, Satoshi Matsusaka, Shingo Dan, Eiji Shinozaki, Hiroyuki Seimiya, Nobuyuki Mizunuma, Kensei Yamaguchi, Toshiharu Yamaguchi
Software Mentions: 1
Published: over 8 years ago
10.1186/s12885-016-2440-9
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programCited by: 82
Author(s): Antoine Adenis, Christelle de la Fouchardière, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant, Jean-Marc Phélip, Andrew Kramar, André Thewis
Software Mentions: 1
Published: over 8 years ago
10.18632/oncotarget.22807
Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenibCited by: 10
Author(s): Hajime Arai, Kunihisa Miyakawa, Tadamichi Denda, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Eguchi Nakajima
Software Mentions: 1
Published: almost 7 years ago
10.1007/s00280-018-3738-x
A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRCCited by: 3
Author(s): Barbara Melosky, Howard John Lim, Janine Marie Davies, Sharlene Gill, Christian Kollmannsberger, Maria Yi Ho, Solomon A. Vandt, Daniel J. Renouf
Software Mentions: 1
Published: almost 6 years ago
10.1371/journal.pone.0190497
Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective studyCited by: 10
Author(s): Chun‐Yu Lin, Tseng‐Hsi Lin, Chou-Chen Chen, Ming-Cheng Chen
Software Mentions: 1
Published: almost 7 years ago
10.3390/cancers12051214
Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerCited by: 25
Author(s): Eleonora Lai, Nicole Liscia, Clelia Donisi, Stefano Mariani, S. Tolu, Andrea Pretta, Mara Persano, Giuliano Pinna, Francesca Balconi, Annagrazia Pireddu, Valentino Impera, Marco Dubois, Marco Migliari, Dario Spanu, Giuseppe Saba, S. Camera, Francesca Musio, Pina Ziranu, Marco Puzzoni, Laura Demurtas, Valeria Pusceddu, Manuela Dettori, Elena Massa, Francesco Atzori, Mariele Dessì, Giorgio Astara, Clelia Madeddu, Mario Scartozzi
Software Mentions: 1
Published: over 4 years ago
10.1186/s40880-017-0263-y
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialCited by: 21
Author(s): Rui‐Hua Xu, Lin Shen, Ke‐Ming Wang, Gang Wu, Shi Chen, Kefeng Ding, Lizhu Lin, Jinwan Wang, Jianping Xiong, Changping Wu, Jin Li, Yunpeng Liu, Dong Wang, Yi Ba, Feng Jiang, Yuxian Bai, Jian Bi, Li Ma, Jian Lei, Qing Yang, Hui Yu
Software Mentions: 1
Published: almost 7 years ago
10.3332/ecancer.2018.875
Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case seriesCited by: 1
Author(s): José Luis Leal, Juan Briones, María Elisa Herrera, Bettina Müller, Bruno Nervi, Sebastián Mondaca
Software Mentions: 1
Published: about 6 years ago